Vistagen Therapeutics Inc
VTGN
NASDAQ
Biotechnology
$0.27
USD
0.00 (+0.49%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.59M
Volume 899.4K
Revenue
$1.27M
TTM
+153.5%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-69.69M
TTM
-35.5%
YoY
Operating Cash Flow
$-66.44M
TTM
-57.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.2 | 0.3 | 0.3 | 0.5 |
YoY Growth | -100.0% | +190.5% | +41.0% | +29.5% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.2 | 0.3 | 0.3 | 0.5 |
Selling, General & Administrative | 0.0 | 4.4 | 4.4 | 5.6 | 4.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 0.0 | 16.0 | 20.3 | 19.8 | 17.2 |
Operating Income | 0.0 | -15.8 | -20.1 | -19.5 | -16.7 |
EBITDA | 0.0 | -15.8 | -20.0 | -19.5 | -16.7 |
Other Income / Expense | 0.0 | -0.0 | 0.0 | 0.0 | -0.0 |
Total Other Income / Expense | 0.0 | 0.7 | 0.6 | 0.6 | 0.5 |
Income Before Income Taxes | 0.0 | -15.1 | -19.4 | -18.9 | -16.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -13.6 | -15.1 | -19.4 | -18.9 | -16.3 |
Consolidated Net Income / Loss | 0.0 | -15.1 | -19.4 | -18.9 | -16.3 |
Net Income Attributable to Common Shareholders | 0.0 | -15.1 | -19.4 | -18.9 | -16.3 |
Basic EPS | $0.00 | -$0.47 | -$0.54 | -$0.45 | -$0.38 |
Diluted EPS | $0.00 | -$0.47 | -$0.54 | -$0.45 | -$0.38 |
Basic Shares Outstanding | 31.6M | 31.9M | 35.7M | 42.2M | 42.4M |
Diluted Shares Outstanding | 31.6M | 31.9M | 35.7M | 42.2M | 42.4M |